MaaT Pharma Secures Capital to Support Commercialization Efforts

MaaT Pharma has successfully raised €9.1 million through a capital increase, issuing 2.62 million new shares at €3.48 each. The majority of the funds were raised from long-standing institutional investors like BPI France, Biocodex, and Invus, who each contributed €1.5 million, along with new investors. This financial boost demonstrates strong confidence in MaaT Pharma's microbiome ecosystem therapeutics, particularly Xervyteg (MaaT013), aimed at treating acute Graft-versus-Host Disease (aGvHD) in Europe.

With net proceeds of approximately €8.7 million, MaaT Pharma extends its cash runway to August 2026, meeting the equity requirement for a €6 million tranche from a European Investment Bank loan. A potential €12 million milestone payment from Clinigen, expected upon EMA approval of Xervyteg in mid-2026, could further enhance the company's financial stability into early 2027.

The funds raised will primarily aid in preparing for Xervyteg's commercialization in Europe, advancing the MaaT033 phase 2b PHOEBUS trial, and coordinating with the FDA for a planned US study. The company is also exploring additional financing options to bolster its pipeline development. First Berlin Equity Research maintains a BUY rating for MaaT Pharma, with a €17 price target representing a 305% potential upside.